Retatrutide Phase 3 Results: 28.7% Weight Loss in TRIUMPH-4 Trial
Eli Lilly's triple agonist retatrutide achieved up to 28.7% average body weight loss in its first successful Phase 3 trial. Seven additional readouts expected throughout 2026. Here's everything researchers need to know.
Eli Lilly announced positive topline results from the Phase 3 TRIUMPH-4 clinical trial on December 11, 2025 — the first successful Phase 3 readout for retatrutide, its investigational triple hormone receptor agonist targeting GIP, GLP-1, and glucagon receptors simultaneously.
What TRIUMPH-4 Found
The 68-week randomized, double-blind, placebo-controlled study enrolled 445 adults with obesity or overweight and knee osteoarthritis. Results were striking:
- Retatrutide 12mg: 28.7% average body weight reduction (-71.2 lbs from a mean baseline of 248.5 lbs)
- Retatrutide 9mg: 26.4% average body weight reduction (-64.1 lbs)
- Placebo: 2.1% weight reduction
Nearly 40% of participants on the 12mg dose achieved ≥30% weight loss — a threshold that was essentially impossible with any prior pharmacological treatment.
Beyond weight loss, retatrutide demonstrated significant reductions in knee osteoarthritis pain (up to 75.8% improvement on WOMAC pain scores), improvements in physical function, and reductions in cardiovascular risk markers including non-HDL cholesterol, triglycerides, and systolic blood pressure.
The Triple Agonist Mechanism
Retatrutide's advantage over semaglutide (GLP-1 only) and tirzepatide (GLP-1 + GIP) lies in its additional glucagon receptor agonism. The glucagon component adds thermogenic and energy expenditure effects that complement the incretin-mediated appetite suppression — a three-pathway metabolic attack that previous compounds couldn't achieve.
Researchers studying metabolic dysfunction will find retatrutide particularly interesting as a tool for understanding how simultaneous activation of all three receptor systems affects body composition, insulin sensitivity, and adipose tissue biology.
Safety Signals to Watch
TRIUMPH-4 identified a notable safety signal: dysesthesia (abnormal sensations) occurred in 8.8% and 20.9% of patients on the 9mg and 12mg doses respectively, compared with 0.7% in placebo. This signal was not observed in Phase 2 trials and is being closely monitored in subsequent TRIUMPH readouts.
Standard GI effects (nausea 43%, diarrhea 33%, vomiting 21%) were consistent with the incretin drug class.
What's Coming in 2026
Seven additional Phase 3 trials in the TRIUMPH program are expected to read out throughout 2026, covering:
- General obesity without comorbidities
- Type 2 diabetes
- Obstructive sleep apnea
- Chronic low back pain
- Cardiovascular and renal outcomes
- Metabolic dysfunction-associated steatotic liver disease (MASLD)
If results are consistently positive, Eli Lilly is expected to submit a New Drug Application in late 2026 or early 2027, with potential FDA approval by mid-to-late 2027.
Research Significance
For the research community, retatrutide represents the most potent pharmacological weight reduction compound demonstrated in controlled trials. Its availability as a research peptide allows laboratory investigation of the triple agonist mechanism before FDA approval makes it commercially available as a prescription drug.
*All products sold by Aeterion Labs are strictly for research purposes only. Not for human consumption.*